Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607398 | 0.88 | MAPT (0.44) | SMN1; SMN2HPGDRAB9ANPC1MAPT | |
| SCHEMBL5606864 | 0.87 | HTT (0.57) | SMN1; SMN2HPGDRAB9ANPC1MAPT | |
| SCHEMBL5607655 | 0.77 | TTR (0.46) | SMN1; SMN2HPGDRAB9ANPC1MAPT | |
| SCHEMBL5606613 | 0.75 | HTT (0.59) | SMN1; SMN2HPGDRAB9ANPC1MAPT | |
| SCHEMBL5606475 | 0.73 | TTR (0.44) | SMN1; SMN2HPGDMAPTLMNAPOLB | |
| SCHEMBL5143263 | 0.72 | TTR (0.55) | HPGDMAPTLMNAPOLBTTR | |
| SCHEMBL8344893 | 0.71 | TSHR (0.57) | SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL5606904 | 0.70 | TTR (0.41) | MAPTLMNATTRKDM4EALDH1A1 | |
| SCHEMBL5607202 | 0.69 | HTT (0.45) | SMN1; SMN2HPGDRAB9ANPC1MAPT | |
| SCHEMBL493835 | 0.69 | HTT (0.69) | SMN1; SMN2NPC1MAPTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | claimed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | SMN1; SMN2 3513/4885HPGD 1451/4885RAB9A 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.